ASCO GU 2024

BRCAAway - practice changing or hypothesis generating data?

Is "more" always better?

Combination vs. monotherapy - a great new option for high-risk patients

Cabo + IO: Interesting but not practice changing?!

Dose de-escalation in different ways

Long-term dose escalation - Therapy in high-risk prostate cancers

Salvage radiation with anti-androgen superior to radiation alone

Insights and news for mCRPC

Evaluating the recombination-repair mutations in patients with mCRPC

Gleason 3+3 - cancer or not?

Higher radiation is effective in high-risk PCA

BRCAaway - PARP combination study

Localized PCa - news for radiotherapy and biochemical recurrence

Further testing before olaparib combination

Still a difficult time for androgenic inhibitors in mCRPC

Olaparib + Arbiraterone better compared to either alone

Combination of cabozantinib & checkpoint inhibitor

What about the clinical benefit?

Relugolix combined with androgen signaling in real word experience

Stockholm3 validated in multiethnic cohort

Cognitive function in ART treatment

Combination NHT + PARP makes sense

Therapy Intensification Still Neglected in mHSPC

First positive study of IO therapy in mCRPC

Enzalutamide therapy as option for biochemical recurrence

Quality of life under intensive therapy

Gleason 3+3 ska vi kalla de cancer eller inte?

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

Kombination av cabozantinib och immunterapi

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

BRCAAway - PARP hämmare, abiraterone eller i kombination

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

Kognitiv påverkan av abirateron och enzalutamid?

ADC + ICI: new data for platinum-refractory bladder cancaer patients

Advances in (neo)-adjuvant treatment in urothelial cancer

The emerging field of biomarkers in bladder cancer

New standard of care, but still open questions!

Another success for an ICI?

ASCO GU24 - Highlights in Bladder cancer

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

EV as standard in 3rd line mUC

MIBC: adjuvant PD1 - all set?!

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

Perioperative adjuvant therapy in urothelial cancer

Update M1 urothelial cancer

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

Update on EV-302

Highlights in bladder cancer at ASCO GU24

EV + Pembro new first-line standard in localized metastatic bladder cancer

HER2 and bladder cancer

Biomarker update

Pembrolizumab adjuvant in bladder cancer

Novedades sobre EV-302

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

Terapia adyuvante perioperatoria en el cáncer de vejiga

Encore un succès pour une ICI ?

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

No surprise with the QoL data

Subcutaneous vs. intravenous application: ready for everyday clinics?

Belzutifan: Updates on QoL

Perioperative treatment in renal cell carcinoma - did we close the circle?

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

Durable effects of Ipi-Nivo

Tumorburden and outcome

Better QoL with Belzutifan

Long-Term Data on NIVO+IPI in aRCC

Practice changing adjuvant therapy?!

Long-term outcome

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Highlights in kidney cancer at ASCO GU24

Overall survival benefit - Pembro after surgery

Long-term follow-up of first-line trials

ASCO GU24 - Highlights in renal cell carcinoma

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?